We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug & Device Products
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Publications
    • Webinar Training Pass
    • eCFR and Guidances
    • Books
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » MHRA Updates Guidance on UK Notified Bodies

MHRA Updates Guidance on UK Notified Bodies

July 7, 2017

In a decision associated with the United Kingdom’s withdrawal from the European Union, the UK’s Medicines & Healthcare products Regulatory Agency issued updated guidance with new links to notified bodies permitted to undertake conformity assessments of medical devices in the UK.

Conformity assessments are required before a CE Mark is issued for marketing authorization. The following notified bodies can conduct conformity assessments in the UK:

  • Amtac Certification Services;
  • BSI Healthcare;
  • Lloyd’s Register Quality Assurance;
  • SGS United Kingdom; and
  • UL International (UK).

The MHRA and the European Medicines Agency are very intertwined, so it will be especially difficult for the MHRA to make a clean break, but it’s unclear how the UK regulatory system will work within the EU regulatory scheme as the UK government negotiates the terms of its withdrawal from the EU. 

BSI said in a statement that its role as an EU notified body won’t change following the UK decision to leave the EU. The standards organization is working closely with the MHRA and the Department of Health to ensure “continuity of our full scope designation” as a notified body for medical devices.

BSI plans to use the existing mechanisms for non-EU member states to fully participate as EU Notified Bodies – and it cites examples of designated organizations in Norway, Switzerland and Australia via mutual recognition agreements, all of whom are recognized as Notified Bodies for the purposes of the EU legislation.

BSI anticipates that the UK will continue to participate in the European standards system post-Brexit. 

Remaining as a full member would bring maximum benefit to the UK economy and society in its new status outside the EU because reciprocity of market access with European countries and the maintenance of a unified domestic market structure across the UK facilitate trade and reduce complexity for SMEs and consumers, BSI said.

BSI expects to be in the first wave of notified bodies designated under the recently passed EU Medical Device and IVD Regulations, and it is investing heavily to meet the new requirements. “Going forward we aim to provide a seamless transition within a new designation recognition mechanism as part of any UK-EU framework,” the standards group said.

The EU’s new Medical Device Regulation has introduced significant compliance headaches for manufacturers — including new harmonized standards, classification rules, and conformity assessment procedures.

Some devices will have to be reclassified under the MDR’s new classification rules. There are four device classifications (I, IIa, IIb, and III) and four groups of classification rules encompassing non-invasive devices, invasive devices, active devices, and a catch-all category of special rules.

Each device class has more than one conformity assessment pathway. There are specific requirements for Class III implantable and Class IIb implantable devices, as well as separate requirements for Class I sterile devices, reusable surgical instruments, and devices that have a measuring function.

View today's stories

Medical Devices Quality

Upcoming Events

  • 08Feb

    Process and Design Validation for Devicemakers: A Deep Dive into Best Practices, Recent Trends and Regulatory Definitions

  • 09Feb

    The Inextricable Link Between Data Integrity and Quality Culture

  • 15Feb

    Advanced Compliance Writing CAPA: Mastering Failure Investigation and Root Cause Analysis

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 22Feb

    Best Practices for Developing and Maintaining a GxP Training Matrix

  • 07Mar

    FDA’s Remote Assessments v. Remote Interactive Evaluations: Do You Really Know the Difference?

Featured Products

  • FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

    FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

  • Selecting and Implementing Electronic Document Management Systems in the EU

    Selecting and Implementing Electronic Document Management Systems in the EU

Featured Stories

  • FDA Issues Update on LivaNova Recall of Blood Pumping System

  • EU Expands Dupixent’s Authorization to Include Eosinophilic Esophagitis

  • MedTrace Receives U.S. Patent for Heart Modeling Method

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell or Share My Data
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing